Your browser is no longer supported. Please, upgrade your browser.
CRNX Crinetics Pharmaceuticals, Inc. weekly Stock Chart
CRNX [NASD]
Crinetics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own5.65% Shs Outstand23.98M Perf Week-3.48%
Market Cap445.07M Forward P/E- EPS next Y-2.83 Insider Trans0.00% Shs Float22.86M Perf Month11.07%
Income-44.40M PEG- EPS next Q-0.66 Inst Own98.49% Short Float8.65% Perf Quarter-2.32%
Sales1.70M P/S261.81 EPS this Y-169.40% Inst Trans1.71% Short Ratio35.16 Perf Half Y-29.64%
Book/sh5.35 P/B3.47 EPS next Y-31.60% ROA-27.90% Target Price39.50 Perf Year-35.47%
Cash/sh5.49 P/C3.38 EPS next 5Y- ROE-30.40% 52W Range14.33 - 36.95 Perf YTD-38.11%
Dividend- P/FCF- EPS past 5Y- ROI-17.90% 52W High-49.77% Beta-
Dividend %- Quick Ratio17.20 Sales past 5Y- Gross Margin- 52W Low29.52% ATR1.06
Employees47 Current Ratio17.20 Sales Q/Q0.00% Oper. Margin- RSI (14)56.65 Volatility7.03% 5.96%
OptionableNo Debt/Eq0.00 EPS Q/Q-88.80% Profit Margin- Rel Volume0.46 Prev Close18.37
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume56.23K Price18.56
Recom2.00 SMA203.20% SMA508.98% SMA200-14.62% Volume25,917 Change1.03%
Feb-14-19Initiated H.C. Wainwright Buy $35
Aug-13-18Initiated Piper Jaffray Overweight $40
Aug-13-18Initiated Leerink Partners Outperform $43
Aug-13-18Initiated JP Morgan Neutral $29
Nov-12-19 06:15PM  Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:04PM  Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-05-19 10:31AM  Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 10:57AM  Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Oct-28-19 11:31AM  We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate Simply Wall St.
Sep-25-19 07:30AM  Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference GlobeNewswire +6.32%
Sep-12-19 08:40AM  What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
Sep-03-19 04:05PM  Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 06:15PM  Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:14PM  Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-19 02:35PM  If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today Simply Wall St.
Jul-29-19 07:30AM  Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism GlobeNewswire -5.72%
Jul-16-19 09:05AM  Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors GlobeNewswire
May-21-19 07:30AM  Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors GlobeNewswire
May-13-19 04:11PM  Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 12:54PM  Heres What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey -5.67%
Mar-19-19 07:30AM  Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly GlobeNewswire
Mar-18-19 07:30AM  Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning GlobeNewswire
Mar-14-19 04:27PM  Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 GlobeNewswire
Mar-13-19 04:05PM  Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 07:30AM  Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference GlobeNewswire -6.51%
Jan-16-19 10:16AM  Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-02-19 04:05PM  Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Nov-21-18 08:20AM  New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.88%
Nov-20-18 07:30AM  Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-13-18 04:05PM  Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +10.85%
Sep-26-18 04:05PM  Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 04:07PM  Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-20-18 04:05PM  Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM  Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE -7.55%
Jul-18-18 11:37AM  Crinetics Pharmaceuticals stock surges 24% in trading debut MarketWatch
07:27AM  Crinetics Pharmaceuticals prices IPO at $17 a share MarketWatch
Jul-17-18 06:55PM  Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.